Colorectal Cancer and Gut Health: Insights from Dr. Richard Birkett

BOSTON, MA / ACCESSWIRE / August 13, 2024 / Colorectal cancer, a serious condition affecting the colon or rectum, is among the most prevalent cancers globally, posing significant risks of severe harm and death. The risk of developing colorectal cancer increases with age, particularly in individuals over 50. Common symptoms include diarrhea, constipation, blood in the stool, abdominal pain, unexplained weight loss, fatigue, and low iron levels. However, early-stage colorectal cancer may not present noticeable symptoms, making regular screenings crucial for early detection. Preventive measures include maintaining a healthy diet, staying physically active, avoiding smoking, limiting alcohol consumption, and undergoing regular screenings. Globally, colorectal cancer is the second leading cause of cancer-related deaths, with over 1.9 million new cases and more than 930,000 deaths reported in 2020. The highest incidence rates are observed in Europe, Australia, and New Zealand, while Eastern Europe has the highest mortality rates. Future projections suggest a troubling increase, with the incidence expected to rise to 3.2 million new cases annually by 2040, accompanied by 1.6 million deaths per year.

Colorectal cancer is increasingly becoming a significant concern, particularly among younger populations. Recent data indicates a troubling rise in colorectal cancer diagnoses in individuals under 50. Addressing this critical health issue, Dr. Richard Birkett, a highly skilled colorectal, general, and trauma surgeon based in Greater Boston, offers his expertise and insights into colorectal cancer, gut health, and the importance of early screening.

Colorectal cancer is no longer a disease confined to older adults. Recent statistics reveal a sharp increase in cases among younger individuals. In the United States, approximately 10% of colorectal cancer cases are diagnosed in people under the age of 50. Moreover, the incidence of young-onset rectal cancer is rising at nearly twice the rate of young-onset colon cancer. Researchers predict that by 2030, colorectal cancer will be the leading cause of cancer deaths among people aged 20-49.

Dr. Richard Birkett, who specializes in laparoscopic and robotic surgery with a focus on GI oncology, GI immunologic diseases, benign diseases of the GI tract, and perioperative physiology, emphasizes the critical importance of early detection and regular screenings. Holding both an MD and MBA, Dr. Birkett’s comprehensive expertise extends to medical device marketing, product development, business development, and evaluation. His experience in developing and executing Sustainability/ESG programs in healthcare and the device industries further enhances his holistic approach to patient care and advocacy.

“In light of the increasing prevalence of colorectal cancer in younger adults, it’s crucial to prioritize early detection and regular screenings,” says Dr. Birkett. “The guidelines for colorectal cancer screening have recently changed, lowering the recommended starting age to 45 for average-risk individuals. This change is a direct response to the alarming rise in diagnoses among younger people.”

The United States Preventive Services Task Force (USPSTF) now recommends that all individuals at average risk begin colorectal cancer screening at age 45. Those at higher risk may need to start earlier. Factors such as ethnicity, lifestyle, and family history can impact when an individual should get screened. It is essential to discuss personal risk factors with a healthcare provider to determine the appropriate screening schedule.

Colorectal cancer is increasingly affecting individuals under 50, making it the only age group with a rising incidence rate. About 10% of colorectal cancer cases in the U.S. are found in those under 50, and the rate of young-onset rectal cancer is nearly twice that of young-onset colon cancer. By 2030, researchers predict that colorectal cancer will be the leading cause of cancer deaths in individuals aged 20-49.

While colonoscopy is considered the gold standard, several screening methods are available. The choice of test depends on age, personal health history, and family background. Starting at age 45 (if at average risk), individuals can choose from stool tests such as FIT, stool-DNA testing (e.g., Cologuard), and FOBT, or visual exams like colonoscopy, virtual colonoscopy, and flexible sigmoidoscopy. Healthcare providers can guide patients in selecting the best screening method for their needs.

You are considered at average risk if you have no symptoms, no family history of colorectal cancer, no personal history of cancer or certain types of polyps, no genetic links to Lynch syndrome, FAP, or other genetic conditions, and no personal history of ulcerative colitis, inflammatory bowel disease, or Crohn’s disease. The standard screening age of 45 applies to those at average risk, but those at higher risk may need to start screening earlier.

The primary hereditary conditions associated with colorectal cancer include Lynch Syndrome, Muir-Torre Syndrome (MTS), MUTYH-Associated Polyposis Syndrome (MAP Syndrome), Familial Adenomatous Polyposis (FAP), Peutz-Jeghers Syndrome, and Li-Fraumeni Syndrome.

Screening is crucial for early detection and prevention of colorectal cancer. Discuss your genetic risk with your healthcare provider to develop a personalized screening plan.

The treatment for colorectal cancer depends on the cancer’s type, stage, and the patient’s overall health. Early detection often leads to better treatment options and outcomes. Treatment options include surgery, typically used in the early stages when the cancer is localized, radiotherapy to shrink tumors before surgery or target cancer cells, chemotherapy to kill or inhibit cancer cells, targeted therapy focusing on specific molecules involved in cancer growth, and immunotherapy to stimulate the body’s immune system to recognize and attack cancer cells. A multidisciplinary approach, involving a team of specialists from various fields, ensures comprehensive care, while supportive care focuses on symptom management, emotional support, and enhancing the overall quality of life for patients and their families.

CONTACT:

https://richard-birkett-md.com/
Email: birkett@richard-birkett-md.com

SOURCE: Richard Birkett

View the original press release on accesswire.com